The Heart Institute, 5702 South Tower, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.
Nat Rev Cardiol. 2010 Jun;7(6):318-26. doi: 10.1038/nrcardio.2010.52. Epub 2010 Apr 27.
Sudden cardiac death (SCD) is a global health issue. The unexpected nature of this devastating condition compounds the urgency of discovering methods for early detection of risk, which will lead to more effective prevention. However, the complex and dynamic nature of SCD continues to present a considerable challenge for the early identification of risk factors. Measurement of the left ventricular ejection fraction (LVEF) is currently the only major risk factor used for stratification in clinical practice. Severely decreased LVEF is likely to manifest late in the natural history of SCD, however, and may only affect a small subgroup of patients who will suffer SCD. A growing body of literature describes novel risk markers and predictors of SCD, such as high-risk phenotypes, genetic variants and biomarkers. This Review will discuss the potential utility of these markers as early identifiers of risk, and suggests a framework for the conduct of future studies for the discovery, validation, and deployment of novel SCD risk factors.
心脏性猝死(SCD)是一个全球性的健康问题。这种破坏性情况的突发性使得发现风险早期检测方法变得更加紧迫,这将导致更有效的预防措施。然而,SCD 的复杂性和动态性仍然对风险因素的早期识别提出了相当大的挑战。目前,左心室射血分数(LVEF)的测量是临床实践中唯一用于分层的主要危险因素。然而,严重降低的 LVEF 可能在 SCD 的自然病史中晚期出现,并且可能仅影响少数将遭受 SCD 的患者。越来越多的文献描述了 SCD 的新的风险标志物和预测因子,如高危表型、遗传变异和生物标志物。这篇综述将讨论这些标志物作为风险早期识别的潜在效用,并提出了一个用于发现、验证和部署新型 SCD 风险因素的未来研究框架。